Influenza vaccine effectiveness against influenza-associated hospitalizations and emergency department or urgent care encounters among children and adults — United States, 2024–25 season

Background: The 2024-25 influenza season was the most severe in the United States (US) since 2017-18, with co-circulation of both influenza A virus subtypes (H1N1 and H3N2). Influenza vaccine effectiveness (VE) has varied by season, setting, and patient characteristics. Methods: Using electronic healthcare encounter data from eight US states, we evaluated influenza vaccine effectiveness (VE) against influenza-associated hospitalizations and emergency department or urgent care (ED/UC) encounters from October 2024-April 2025 among children aged 6 months-17 years and adults aged ≥18 years. Using a test-negative, case-control design, we compared the odds of influenza vaccination between acute respiratory illness (ARI) encounters with a positive (cases) versus negative (controls) test for influenza by molecular assay, adjusting for confounders. Results: Analyses included 108,618 encounters (5,764 hospitalizations and 102,854 ED/UC encounters) among children and 309,483 encounters (76,072 hospitalizations and 233,411 ED/UC encounters) among adults. Among children across care settings, 17.0% (6,097/35,765) of cases versus 29.4% (21,449/72,853) of controls were vaccinated. Among adults, 28.2% (21,832/77,477) of cases versus 44.2% (102,560/232,006) of controls were vaccinated. VE was 51% (95% confidence interval [95% CI]: 41-60%) against influenza-associated hospitalizations and 54% (95% CI: 52-55%) against influenza-associated ED/UC encounters among children. VE was 43% (95% CI: 41-46%) against influenza-associated hospitalizations and 49% (95% CI: 47-50%) against influenza-associated ED/UC encounters among adults. Conclusions: Influenza vaccination provided protection against influenza-associated hospitalizations and ED/UC encounters among children and adults in the US during the severe 2024-25 influenza season.These findings support influenza vaccination as an important tool to reduce influenza-associated disease. Brief Summary: During the 2024-25 influenza season, influenza vaccination provided protection against influenza-associated hospitalizations (43-51%) and emergency department or urgent care encounters (49-54%) among children and adults in the United States.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-04-24
DOI
https://doi.org/10.64898/2026.04.22.26350853
Primary Topic
Influenza Virus Research Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Influenza vaccine effectiveness against influenza-associated hospitalizations and emergency department or urgent care encounters among children and adults — United States, 2024–25 season

Allison L. Naleway, Brendan Flannery, Inih Essien, Ousseny Zerbo et al.
medRxiv
Influenza Virus Research Studies
article

Influenza vaccine effectiveness against influenza-associated hospitalizations and emergency department or urgent care encounters among children and adults — United States, 2024–25 season

Allison L. Naleway, Brendan Flannery, Inih Essien, Ousseny Zerbo, Lindsey Kirshner, Caitlin Ray, Lina S. Sy, Michelle A. Barron, Sara Y. Tartof, Thomas J. Duszynski, Nicola P. Klein, Malini B. DeSilva, John Hansen, Zachary A. Weber, Shaun J. Grannis, Colin Rogerson, Stephanie A. Irving, Julie Arndorfer, Omobosola Akinsete, Daniel Bride, Jennifer DeCuir, Karthik V. Natarajan, Kristin Dascomb, Richard Contreras, Tamara Sheffield, Sarah Ball, Charlene McEvoy, St Salas, Duck‐Hye Yang, Josh Van Otterloo, Adam Yates, David Mayer, Toan Ong, Brian E. Dixon, Emily L. Reeves, Karen B. Jacobson, Lawrence Block, Shikha Garg, Catia Chavez, Padma Koppolu, Amanda B. Payne, Bruno Lewin, Katherine Adams, William F. Fadel
article en

Abstract

Background: The 2024-25 influenza season was the most severe in the United States (US) since 2017-18, with co-circulation of both influenza A virus subtypes (H1N1 and H3N2). Influenza vaccine effectiveness (VE) has varied by season, setting, and patient characteristics. Methods: Using electronic healthcare encounter data from eight US states, we evaluated influenza vaccine effectiveness (VE) against influenza-associated hospitalizations and emergency department or urgent care (ED/UC) encounters from October 2024-April 2025 among children aged 6 months-17 years and adults aged ≥18 years. Using a test-negative, case-control design, we compared the odds of influenza vaccination between acute respiratory illness (ARI) encounters with a positive (cases) versus negative (controls) test for influenza by molecular assay, adjusting for confounders. Results: Analyses included 108,618 encounters (5,764 hospitalizations and 102,854 ED/UC encounters) among children and 309,483 encounters (76,072 hospitalizations and 233,411 ED/UC encounters) among adults. Among children across care settings, 17.0% (6,097/35,765) of cases versus 29.4% (21,449/72,853) of controls were vaccinated. Among adults, 28.2% (21,832/77,477) of cases versus 44.2% (102,560/232,006) of controls were vaccinated. VE was 51% (95% confidence interval [95% CI]: 41-60%) against influenza-associated hospitalizations and 54% (95% CI: 52-55%) against influenza-associated ED/UC encounters among children. VE was 43% (95% CI: 41-46%) against influenza-associated hospitalizations and 49% (95% CI: 47-50%) against influenza-associated ED/UC encounters among adults. Conclusions: Influenza vaccination provided protection against influenza-associated hospitalizations and ED/UC encounters among children and adults in the US during the severe 2024-25 influenza season.These findings support influenza vaccination as an important tool to reduce influenza-associated disease. Brief Summary: During the 2024-25 influenza season, influenza vaccination provided protection against influenza-associated hospitalizations (43-51%) and emergency department or urgent care encounters (49-54%) among children and adults in the United States.

medRxiv
Intermountain Healthcare (US), Centers for Disease Control and Prevention (US), Regenstrief Institute (US), Westat (United States) (US), NewYork–Presbyterian Hospital (US), Kaiser Permanente (US), National Center for Immunization and Respiratory Diseases (US), Columbia University Irving Medical Center (US), Kaiser Permanente Center for Health Research (US), Richard M. Fairbanks Foundation (US), University of Colorado Anschutz Medical Campus (US), HealthPartners (US), Indiana University – Purdue University Indianapolis (US)
Kaiser Permanente
Good health and well-being
Openalex Percentile: Top 13%
Influenza Virus Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.